CalciMedica financials
$1.61−4.17%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.0M | -$5.6M | -$4.4M | -$5.6M | -$6.6M | -$6.5M | -$6.2M | -$5.7M | -$6.5M | -$5.8M | -$4.3M | -$4.8M |
| Net income | -$7.7M | $5.0M | -$10.8M | -$7.8M | -$6.0M | -$5.0M | -$4.3M | -$5.6M | -$4.0M | $130.0K | -$4.1M | -$4.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.25 | $1.50 | $-3.39 | $-2.60 | $-2.00 | $-1.80 | $-1.68 | $-2.50 | $-1.80 | $0.05 | $-3.58 | $-4.10 |
| EBITDA | -$4.0M | -$5.6M | -$4.4M | -$5.6M | -$6.6M | -$6.5M | -$6.2M | -$5.7M | -$6.5M | -$5.8M | -$4.3M | -$4.8M |
| Operating cash flow | -$4.6M | -$4.9M | -$4.9M | -$4.8M | -$6.7M | -$4.9M | -$5.0M | -$4.7M | -$6.8M | -$4.7M | -$3.6M | -$4.6M |
| Free cash flow | -$4.6M | -$4.9M | -$4.9M | -$4.8M | -$6.7M | -$4.9M | -$5.0M | -$4.7M | -$6.8M | -$4.7M | -$3.6M | -$4.6M |
| Diluted shares | 3.4M | 3.3M | 3.2M | 3.0M | 3.0M | 2.8M | 2.5M | 2.2M | 2.2M | 2.0M | 1.2M | 1.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.6M | $8.2M | $11.5M | $5.5M | $5.9M | $12.6M |
| Short-term investments | $0.00 | $0.00 | $1.5M | $8.6M | $12.0M | $12.1M |
| Total debt | $9.2M | $6.7M | $9.7M | $8.9M | $8.5M | $8.6M |
| Total assets | $19.5M | $8.6M | $13.6M | $14.9M | $19.1M | $25.3M |
| Total liabilities | $14.0M | $9.7M | $20.2M | $15.2M | $13.0M | $14.5M |
| Shareholders' equity | $5.5M | -$1.1M | -$6.6M | -$268.0K | $6.1M | $10.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology